1. Home
  2. RYTM vs HIW Comparison

RYTM vs HIW Comparison

Compare RYTM & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • HIW
  • Stock Information
  • Founded
  • RYTM 2008
  • HIW 1978
  • Country
  • RYTM United States
  • HIW United States
  • Employees
  • RYTM N/A
  • HIW N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • HIW Real Estate Investment Trusts
  • Sector
  • RYTM Health Care
  • HIW Real Estate
  • Exchange
  • RYTM Nasdaq
  • HIW Nasdaq
  • Market Cap
  • RYTM 3.2B
  • HIW 3.1B
  • IPO Year
  • RYTM 2017
  • HIW 1994
  • Fundamental
  • Price
  • RYTM $52.70
  • HIW $29.79
  • Analyst Decision
  • RYTM Strong Buy
  • HIW Buy
  • Analyst Count
  • RYTM 12
  • HIW 7
  • Target Price
  • RYTM $68.58
  • HIW $30.86
  • AVG Volume (30 Days)
  • RYTM 544.5K
  • HIW 1.2M
  • Earning Date
  • RYTM 05-06-2025
  • HIW 04-22-2025
  • Dividend Yield
  • RYTM N/A
  • HIW 6.84%
  • EPS Growth
  • RYTM N/A
  • HIW N/A
  • EPS
  • RYTM N/A
  • HIW 0.94
  • Revenue
  • RYTM $130,126,000.00
  • HIW $830,020,000.00
  • Revenue This Year
  • RYTM $47.06
  • HIW $0.03
  • Revenue Next Year
  • RYTM $68.10
  • HIW $5.34
  • P/E Ratio
  • RYTM N/A
  • HIW $31.10
  • Revenue Growth
  • RYTM 68.06
  • HIW N/A
  • 52 Week Low
  • RYTM $35.17
  • HIW $23.52
  • 52 Week High
  • RYTM $68.58
  • HIW $36.78
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.00
  • HIW 52.80
  • Support Level
  • RYTM $52.54
  • HIW $28.95
  • Resistance Level
  • RYTM $55.21
  • HIW $29.74
  • Average True Range (ATR)
  • RYTM 2.05
  • HIW 0.70
  • MACD
  • RYTM 0.36
  • HIW 0.09
  • Stochastic Oscillator
  • RYTM 47.82
  • HIW 76.30

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About HIW Highwoods Properties Inc.

Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties' largest customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.

Share on Social Networks: